

Ref: FOI/GS/ID 7734

Please reply to: FOI Administrator Trust Management Maidstone Hospital Hermitage Lane Maidstone, Kent ME16 9QQ Email: mtw-tr.foiadmin@nhs.net www.mtw.nhs.uk

03 November 2022

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Biologic medicines in gastroenterology.

You asked:

Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- a. Adalimumab Humira
- b. Adalimumab Biosimilar
- c. Filgotinib
- d. Golimumab
- e. Infliximab Remicade
- f. Infliximab Biosimilar
- g. Ozanimod
- h. Tofacitinib
- i. Ustekinumab
- j. Vedolizumab

Q2 If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Ulcerative Colitis ONLY with the following biologic drugs:

- a. Adalimumab Humira
- b. Adalimumab Biosimilar
- c. Filgotinib
- d. Golimumab
- e. Infliximab Remicade
- f. Infliximab Biosimilar
- g. Ozanimod
- h. Tofacitinib
- i. Ustekinumab

j. Vedolizumab

Trust response:

Q1 and Q2.

Under Section 21 of the Act we are not required to provide information in response to a request if the information is already reasonably accessible to you. The information you requested is available from the trust website using the following link/s: <u>https://www.mtw.nhs.uk/freedom-of-information/recent-foiresponses/</u> the link should take you to the Data to Support FOI FAQ's page where you need to click on the Pharmacy dropdown.

Alternatively, from our website home page, click the Freedom of Information Tab, then the Data to Support FOI FAQ's tab and then the Pharmacy dropdown at the bottom of the page where you will find all the information.

The information for April 2022 to September 2022 is currently being updated and is exempt under Section 22 of the Act.